Anhui Huaheng Bio’s initial public offering application was approved by the Shanghai Stock Exchange, and the company will be listed on the SSE Science and Technology Board. Huaheng Bio is a high-tech enterprise mainly engaged in the research and development, production, and sales of amino acids and their derivatives. The main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin, which can be widely used in many fields, such as medicine, healthcare products, food additives, and others. The company intends to use the IPO raising to invest RMB 570 million yuan (USD $88 million) for the alanine production capacity project, valine project, fermentation alanine technical reform and expansion project, and supplementary working capital. (Source: ipo123.cn)

Comments are closed.